Phyton Biotech specializes in Plant Cell Fermentation (PCF®) technology, which is a proprietary and sustainable method for producing high-value phytochemicals. This innovative approach allows the company to overcome supply constraints associated with traditional plant extraction methods, particularly for active compounds derived from rare or endangered plant species. By utilizing a proprietary library of plant cell cultures, Phyton can ensure consistent quality and compliance with regulatory standards through strictly controlled GMP-compliant processes. Their PCF® technology is scalable, enabling production from small quantities to large commercial volumes, making it a cost-competitive solution for various industries, including pharmaceuticals and cosmetics.

In addition to its core PCF® technology, Phyton Biotech offers comprehensive development services that encompass the entire production chain, from feasibility studies to commercial manufacturing. Their capabilities include sourcing and selecting optimal plant materials, developing high-yielding cell lines, and scaling up production processes. The company is recognized as the largest global supplier of Paclitaxel and Docetaxel, producing these active pharmaceutical ingredients (APIs) without relying on vulnerable plant sources. Phyton's commitment to environmentally responsible biotechnology and its expertise in custom process development further enhance its position as a leader in the field of specialty fermentation solutions.

Germany

Phyton Biotech is the world's leader in pharmaceutical plant cell fermentation (PCF®) technology.  A global supplier of high quality oncology actives via PCF, our products are registered in every major country in the world.  With state-of-the-art facilities near Hamburg  and Vancouver, we also offer comprehensive development services via PCF for plant-based actives, complex small molecules, and a variety of products used in the treatment of cancer and other serious illnesses.

Phyton Biotech

Company Details